TP53 and gastric cancer: &lt;i&gt;In vitro&lt;/i&gt; screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives &lt;i&gt;CDKN1&lt;/i&gt; and &lt;i&gt;BBC3&lt;/i&gt; expression to restore a p53-dependent cytotoxicity.